[1] XU W,ATKINS MB,MCDERMOTT DF.Checkpoint inhibitor immunotherapy in kidney cancer [J].Nat Rev Urol,2020,17(3):137-150.
[2] 吕磊,郑福鑫,向威,等.免疫相关基因CEBPB在肾透明细胞癌中的表达及其临床价值[J].中华泌尿外科杂志,2021,42(11):849-855.
LYU L,ZHENG FX,XIANG W,et al.Prognosis value of immune-related gene CEBPB in clear cell renal cell carcinoma [J].Chinese Journal of Urology,2021,42(11):849-855.
[3] QI X,QIC,WU T,et al.CSF1R and HCST:Novel candidate biomarkers predicting the response to immunotherapy in non-small cell lung cancer[J].Technol Cancer Res Treat,2020,19:1533033820970663.
[4] LANIER LL.NKG2D receptor and its ligands in host defense [J].Cancer Immunol Res,2015,3(6):575-582.
[5] LANIER LL.DAP10- and DAP12-associated receptors in innate immunity [J].Immunol Rev,2009,227(1):150-160.
[6] CAO WY,LI CD,WANG J.Structure and function of NKG2D [J].Chinese Journal of Immunology,2019,35(6):760-766.
[7] SAKAGUCHI M,MURATA H,AOYAMA Y,et al.DNAX-activating protein 10 (DAP10) membrane adaptor associates with receptor for advanced glycation end products (RAGE) and modulates the RAGE-triggered signaling pathway in human keratinocytes [J].J Biol Chem,2014,289(34):23389-23402.
[8] SHI N,LUO Y,XU Y,et al.DAP10 predicted the outcome of pediatric B-cell acute lymphoblastic leukemia and was associated with the T-cell exhaustion [J].J Oncol,2021,2021:4824868.
[9] ZHANG FF,JI CW,ZHAO XZ,et al.Advances in the research of immunocheckpoint inhibitors in advanced renal cell cancer [J].Chinese Journal of Surgical Oncology,2020,12(5):480-488.
[10] 韩松辰,殷华奇,徐涛. 基于肾癌肿瘤微环境的免疫治疗研究进展[J].中国医学科学院学报,2022,44(2):305-312.
HAN SC,YIN HQ,XU T.Immunotherapy based on tumor microenvironment in renal cell carcinoma [J].Acta Academiae Medicinae Sinicae,2022,44(2):305-312.
[11] PHILIP M,SCHIETINGER A.CD8+ T cell differentiation and dysfunction in cancer [J].Nat Rev Immunol,2022,22(4):209-223.
[12] DOLINA JS,VAN BRAECKEL-BUDIMIR N,THOMAS GD,et al.CD8+T cell exhaustion in cancer[J].Front Immunol,2021,12:715234.
[13] NI HB,FENG H.Biological characteristics of tumor infiltrating regulatory T cells and the application of regulatory T cells in tumor immunotherapy [J].Cancer Research and Clinic,2021,33(5):397-400.
[14] TOGASHI Y,SHITARA K,NISHIKAWA H,et al.Regulatory T cells in cancer immunosuppression- implications for anticancer therapy [J].Nat Rev Clin Oncol,2019,16(6):356-371.
[15] MELAIU O,LUCARINI V,CIFALDI L,et al.Influence of the tumor microenvironment on NK Cell function in solid tumors [J].Front Immunol,2020,10:3038.
[16] DEVILLIER R,CHRETIEN AS,PAGLIARDINI T,et al.Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy [J].J Leukoc Biol,2021,109(6):1071-1088.
[17] WHERRY EJ.T cell exhaustion [J].Nat Immunol,2011,12(6):492-499.